Zcchc11 deficiency decreases IGF-1 expression <i>in vivo</i>. by Matthew R. Jones (115795)

“…<p>(A) IGF-1 mRNA, measured by qRT-PCR, was decreased by Zcchc11 deficiency in 8-day-old livers. …”

RNF5 loss decreases ERK and Akt activation, CDK1 and Smo expression and KSHV lytic replication in PEL cells. by Xiaojuan Li (351842)

Inhibition of SNAI2 expression decreases the sensitivity to chemotherapy drugs of HCC cells. by Xin-Yu Zhao (3228756)

Decreased muscle strength is associated with proinflammatory cytokines but not testosterone levels in men with diabetes by J.P. Ferreira (5550653)

The ratio of standard deviation to mean dose (SD/mean) decreases with neuronal dose. by Murat Alp (781371)

Superoxide production is decreased with pregnancy and remains low seven days after parturition. by Andrea Iorga (298552)

Survival and average length of <i>Cesmn-1(lf)</i> animals is decreased. by Maria Dimitriadi (238530)

Adult AC3^−/− mice exhibit decreased locomotor activity. by Zhenshan Wang (257654)

SN09-2 decreases mitochondrial membrane potential and induces ROS generation. by Sumi Park (420314)

Gefitinib and erlotinib decreased cyclin-D1 without activation of caspase-3. by Satoshi Koyama (784927)

Treatment with con-G showed improved neurological scoring and decreased peri-infarct Ca²⁺ microdeposits. by Rashna Balsara (714796)

Simulated effects of increased pCREB combined with decreased pCaMKIIα on bistability. by Yili Zhang (540283)

“…<p>(A1) Modification of model. Increased basal phosphorylation of CREB <i>k</i>_{<i>basalp_creb</i>}, concurrent with decreased basal phosphorylation of CaMKIIα <i>k</i>_{<i>basalp_CaMKII</i>}, in the absence of the effects of MeCP2/HDAC2/Sin3a (red) ([<i>E</i>_<i>comp</i>] = 0; [<i>E</i>_<i>MeCP2</i>] = 0). …”

Biodentine^® suspensions decreased the concentration of the N-terminal domain of pro-collagen type I (P1NP). by Frangis Nikfarjam (3390854)

Necdin deficiency decreases <i>p16</i> expression and increases <i>Cdk1</i> expression in the embryonic neocortex. by Ryohei Minamide (505053)

Necdin deficiency decreases <i>p16</i> expression and increases <i>Cdk1</i> expression in primary NPCs. by Ryohei Minamide (505053)

Decreased by Violet R. Mukaro (282939)

List of Included studies. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

The search strategy in three databases. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

NIH score. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

List of excluded studies. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”